GTx Files Toremifene For Prostate Cancer-Related Bone Loss
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GTx is looking to be first to market with a treatment for prostate cancer patients that helps prevent common and debilitating fractures caused by androgen deprivation therapy.